A Study to Assess the Concentration of Budesonide in Breast Milk From Asthmatic Women

AstraZeneca

Status and phase

Completed

Phase 4

Conditions

Asthma

Treatments

Drug: Pulmicort (budesonide) Turbuhaler

Study type

Interventional

Funder types

Industry

Identifiers

NCT00228475

D5254C00763

Details and patient eligibility

About

The purpose to measure the concentration of budesonide in breast milk of asthmatic mothers on their normal maintenance treatment with budesonide (Pulmicort Turbuhaler), and to estimate the exposure of budesonide to infants.

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

Be willing and able to comply with study procedures and provide informed consent.
Be breast-feeding women, aged 18 to 45 years inclusive, and having infants aged 1 to 6 months.
Be asthmatics that have been on maintenance treatment with Pulmicort Turbuhaler 200 or 400 µg bid for at least 3 months prior to visit

Exclusion criteria

Clinically relevant abnormalities in physical examination, laboratory assessments, blood pressure or pulse as judged by the investigator.
Clinically relevant disease and/or abnormalities, which in the opinion of the investigator, may either put the patient or infant at risk because of participation in the study or may influence the results of the study or the patient's ability to participate in the study.
A suspected/manifested infection of HIV, hepatitis B or C or other infection according to WHO Risk classification 2-4